The new Cuban vaccine for the treatment of chronic hepatitis B is currently undergoing clinical trials in Cuba and eight Asian countries, with the cooperation of the French company Abivax.
Researchers say the new product – HeberNasvac, developed by researchers of the Center for Genetic Engineering and Biotechnology (CIGB), has proved to be more effective and safer than the rest of those existing in the world against the illness.
According to the World Health Organization, chronic liver disease caused by the hepatitis B virus is one of the main causes of liver cancer.
Taiwan National Day Celebration
